Our study aims to evaluate the cardiac safety of trastuzumab biosimilars in a real-world setting by assessing treatment-related LVEF decline, providing practical insights into HER2-positive early breast cancer management, especially in balancing cost and toxicity considerations. The gene discussed is ERBB2; the disease is breast carcinoma.